MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue GuidanceGlobeNewsWire · Oct 15, 2026
Comparing MDxHealth (NASDAQ:MDXH) & Shattuck Labs (NASDAQ:STTK)Defense World · Oct 2, 2026
MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'Benzinga · Aug 14, 2026
MDxHealth SA (MDXH) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 13, 2026
MDxHealth SA (MDXH) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research · Aug 13, 2026
Mdxhealth Reports Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 13, 2026MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool.